- We will send in 10–14 business days.
/images/books/13036170/9783319158044.jpg)
- Author: James Leong
- Publisher: Adis
- Year: 2015
- Pages: 317
- ISBN-10: 331915804X
- ISBN-13: 9783319158044
- Format: 15.6 x 23.4 x 1.9 cm, kieti viršeliai
- Language: English
- SAVE -10% with code: EXTRA
Reviews
Description
This book proposes and investigates a universal framework, and accompanying documentation system, to facilitate and catalogue benefit-risk decisions; a valuable addition to the benefit-risk toolbox.
Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view to developing a structured, systematic, standardized approach. Examining the evaluation of such an approach by several mature regulatory authorities ensures that the reader gains a unique insight into the ongoing debate in this area.
The field of benefit-risk assessment continues to evolve at a rapid pace due to political and societal pressure, as is reflected in the recent FDA PUDFA agreement as well as in the EMA 2015 Roadmap. Rather than provide a comprehensive snap-shot of this constantly changing environment, this book evaluates selected current approaches to benefit-risk assessment. The strengths and weaknesses of publicly available documents in communicating benefit-risk decisions to stakeholders are reviewed and these evaluations are used to inform development of a prospective framework that could be used to harmonise procedures globally.EXTRA 10 % discount with code: EXTRA
The promotion ends in 22d.06:15:01
The discount code is valid when purchasing from 10 €. Discounts do not stack.
- Author: James Leong
- Publisher: Adis
- Year: 2015
- Pages: 317
- ISBN-10: 331915804X
- ISBN-13: 9783319158044
- Format: 15.6 x 23.4 x 1.9 cm, kieti viršeliai
- Language: English English
This book proposes and investigates a universal framework, and accompanying documentation system, to facilitate and catalogue benefit-risk decisions; a valuable addition to the benefit-risk toolbox.
Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view to developing a structured, systematic, standardized approach. Examining the evaluation of such an approach by several mature regulatory authorities ensures that the reader gains a unique insight into the ongoing debate in this area.
The field of benefit-risk assessment continues to evolve at a rapid pace due to political and societal pressure, as is reflected in the recent FDA PUDFA agreement as well as in the EMA 2015 Roadmap. Rather than provide a comprehensive snap-shot of this constantly changing environment, this book evaluates selected current approaches to benefit-risk assessment. The strengths and weaknesses of publicly available documents in communicating benefit-risk decisions to stakeholders are reviewed and these evaluations are used to inform development of a prospective framework that could be used to harmonise procedures globally.
Reviews